29 September 2017 - In the third in her series of five articles, Leela Barham considers the extent to which the third of the UK PPRS’ objectives – to keep the branded medicines bill within affordable limits – has been met.

The Pharmaceutical Price Regulation Scheme (PPRS) is a voluntary agreement between the Association of the British Pharmaceutical Industry (ABPI) and the UK government, represented by the Department of Health (DH). It’s third objective is to ‘improve access to innovative medicines commensurate with the outcomes they offer patients by ensuring that medicines approved by NICE are available widely in the NHS’. So has the 2014 PPRS delivered on its commitment to improved access?

Read Pharmaphorum article